|
Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study. |
|
|
Honoraria - Bio-Rad; Chugai Pharma; Guardant Health; Sysmex |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; DropWorks; Genentech/Roche; GRAIL; Ignyta; Inivata; LOXO; Novartis; Takeda |
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - GRAIL; Thermo Fisher Scientific |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - GRAIL; Illumina |
|
|
|
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
Research Funding - Eisai (Inst); GRAIL (Inst); Janssen Diagnostics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Agena Bioscience; Celgene; Cynvenio Biosystems; GRAIL; Menarini Silicon Biosystems; Merck |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Insys Therapeutics; IntegraGen; Lilly; Merrimack; Pharmacyclics |
Speakers' Bureau - Celgene |
|
|
Research Funding - Celgene (Inst); Eisai (Inst); Genentech/Roche (Inst); GRAIL (Inst); Janssen/Veridex (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst) |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
Employment - GRAIL; Myriad Genetics |
Stock and Other Ownership Interests - GRAIL; Myriad Genetics |
|
|
Stock and Other Ownership Interests - Achilles Therapeutics; Apogen Biotechnologies; Epic Sciences; GRAIL |
Honoraria - Boehringer Ingelheim; Celgene; GlaxoSmithKline; Lilly; Ono Pharmaceutical; Pfizer; Roche; SERVIER |
Consulting or Advisory Role - Genentech/Roche |
Research Funding - Boehringer Ingelheim |
Patents, Royalties, Other Intellectual Property - Founder of Achilles Therapeutics: a biotechnology company funded by Syncona/Wellcome Trust to target clonal Neoantigens through vaccine and cell therapy approaches; Patent WO2016174085 A1: Method for treating cancer based on identification of clonal neo-antigens; Patent WO2017042394 A1 :Methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention |